Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

Delayed Quote. Delayed  - 11/17 10:00:00 pm
11.75 USD   -2.08%
11/13 Immunomedics Announces Presentations and Investor Event at the 20..
11/10 IMMUNOMEDICS : Leaps Despite Q1 Loss
11/09 IMMUNOMEDICS : reports 1Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Immunomedics : Leaps Despite Q1 Loss

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 09:27pm CET
Immunomedics, Inc. (NASDAQ: IMMU) shares spiked in Friday trading on first quarter numbers Total costs and expenses for the first quarter ended September 30, 2017 were $22.3 million, compared to $15.7 million for the same quarter in fiscal 2017, an increase of approximately 42%. Net loss attributable to stockholders was $118.7 million, or approximately $0.97 per share, for the first quarter ended September 30, 2017, compared to $16.2 million, or approximately $0.17 per share, for the same quarter in fiscal 2017, an increase of approximately 633%. Cash, cash equivalents, and marketable securities totaled $139.6 million as of September 30, 2017. Chairman Behzad Aghazadeh said, “During the quarter and over the course of the year, we have made significant progress toward preparing a BLA for accelerated approval of IMMU-132, our breakthrough therapy candidate for the treatment of late-stage metastatic triple-negative breast cancer (mTNBC). "IMMU-132 has shown a remarkable response rate in patients and we remain sharply focused on bringing this promising treatment to market as soon as possible. Notably, in the quarter, we completed a number of successful meetings with the (Food and Drug Administration) including a CMC and a pre-BLA meeting, where we received positive feedback on our proposed submission plans. As such, we remain on track to meet our stated goal of submitting our BLA filing in the first quarter.” Shares gained $2.03, or 19.4%, to $12.47.

Copyright © 2017 Baystreet.ca Media Corp. All rights reserved., source Standard Equities Feed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
11/14 IMMUNOMEDICS : Announces Presentations and Investor Event at the 2017 San Antoni..
11/13 IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Change in Directo..
11/13 Immunomedics Announces Presentations and Investor Event at the 2017 San Anton..
11/11 IMMUNOMEDICS : names ex-Celgene exec its new CEO
11/10 IMMUNOMEDICS : Leaps Despite Q1 Loss
11/09 IMMUNOMEDICS : reports 1Q loss
11/09 IMMUNOMEDICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
11/09 IMMUNOMEDICS INC : Results of Operations and Financial Condition, Financial Stat..
11/09 Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corpora..
11/09 Immunomedics Appoints Michael Pehl President and Chief Executive Officer to L..
More news
News from SeekingAlpha
11/17 YOUR DAILY PHARMA SCOOP : Gilead CAR-T Potential, Egalet Surges, Aerie Launches ..
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/14 Immunomedics Emerges With New Leadership
11/13 Wells defends Immunomedics, 19% selloff a "buying opportunity"
11/13 Midday Gainers / Losers
Financials ($)
Sales 2018 15,0 M
EBIT 2018 -97,8 M
Net income 2018 -154 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 119x
Capi. / Sales 2019 50,4x
Capitalization 1 786 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,0 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Michael Pehl Chief Executive Officer-Designee
Behzad Aghazadeh Chairman
Michael R. Garone Chief Financial Officer & Vice President
David M. Goldenberg Director, Chief Scientific & Patent Officer
William A. Wegener Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.220.16%1 786
CELLTRION, INC.--.--%24 558
INCYTE CORPORATION5.19%22 258
IQVIA HOLDINGS INC37.36%22 074
LONZA GROUP59.52%19 560
ALNYLAM PHARMACEUTICALS, INC.240.57%12 538